ArticleDiscover oncology2026
Bioinformatics and clinical analysis reveal the potential diagnostic and prognostic role of DLD for pan cancer and renal carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCuprotosis is recognized as a novel form of programmed cell death pathway. Dihydrolipoamide dehydrogenase (DLD) functions as a critical gene regulating cuprotosis. Here, we designed to analyze the utility of consideration of the prognostic and immunological significance of cuproptosis-related gene DLD across human cancers.
methodsUtilizing the TCGA, GTEx, and HPA databases, this study systematically evaluated DLD expression at both the mRNA and protein levels. Our analysis leveraged TCGA data to explore how DLD relates to survival, clinical features, immune infiltration, and DNA methylation in pan-cancer. Single-cell sequencing data from TISCH complemented this by resolving DLD expression at the cellular level. Experimental validation in KIRC was conducted via IHC, western blot, and qRT-PCR. Together, these approaches aimed to define the oncogenic role of DLD, particularly in KIRC. The Wilcoxon rank sum test, Pearson correlation test are used to teste differences among groups and correlations. The Kaplan–Meier method is used to estimate the relationship between patient prognosis and DLD expression levels.
resultsDLD exhibits elevated expression across multiple malignancies, and its high expression consistently correlates with improved clinical prognosis (p < 0.05). Bioinformatic analyses further show significant correlations between DLD expression and the activity of cancer-related pathways, as well as immunological interactions including cancer-associated fibroblasts, immune cell infiltration, and immune checkpoint genes. Single-cell analysis suggests DLD likely participates in angiogenesis, cell cycle regulation, differentiation, DNA damage, DNA repair, and hypoxia responses. Notably, experimental validation confirms significantly lower DLD expression in KIRC tissues. Moreover, DLD expression correlates significantly with TNM stage, pathological stage, histologic grade, and primary therapy outcome (all p < 0.05).
conclusionsThe cuproptosis-related gene DLD may be a potential diagnostic and prognostic biomarker for pan-cancer. Furthermore, it may serve as an independent risk factor for poor outcomes of KIRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.